Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06957327 · ClinicalTrials.gov registry record · Phase 1
A Study of ERAS-601 in People With Chordoma
A Phase 1 study of Chordoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 7
- Study locations
NCT06957327 is a Phase 1 study of Chordoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 46 participants, below the 84-participant average among 15 other Chordoma trials with a reported enrollment target (45% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06957327, a Phase 1 study of Chordoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
Conditions Studied
Interventions
- DRUG ERAS-601
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-04-25 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06957327
The ClinicalTrials.gov registry entry for NCT06957327 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 84-participant average among 15 other Chordoma trials with a reported enrollment target (45% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chordoma appearing as the primary indexed condition, and to 1 intervention - of which ERAS-601 is the first listed.
NCT06957327 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06957327 about?
NCT06957327 is a clinical study titled "A Study of ERAS-601 in People With Chordoma". The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
What is the current status of trial NCT06957327?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2025-04-25. Estimated completion is 2027-04.
What conditions does trial NCT06957327 study?
This clinical trial studies the following conditions: Chordoma.
What interventions are being tested in trial NCT06957327?
The interventions under investigation include: ERAS-601 (DRUG).
Who is sponsoring clinical trial NCT06957327?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06957327 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
ACTIVE NOT RECRUITING · Phase 1
-
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
COMPLETED · Phase 1
-
Nilotinib With Radiation for High Risk Chordoma
COMPLETED · Phase 1
-
Children and Adults With Chordoma
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.